The DOI matches its Crossref record; 47 of the 49 references it cites were found in a registry or an index, and 1 are not checked yet.
Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification
Open accessAbstract
Objective: We previously reported a characterisation of the hepatocellular carcinoma (HCC) immune contexture and described an immune-specific class. We now aim to further delineate the immunogenomic classification of HCC to incorporate features that explain responses/resistance to immunotherapy. Design: We performed RNA and whole-exome sequencing, T-cell receptor (TCR)-sequencing, multiplex immunofluorescence and immunohistochemistry in a novel cohort of 240 HCC patients and validated our results in other cohorts comprising 660 patients. Results: Our integrative analysis led to define: (1) the inflamed class of HCC (37%), which includes the previously reported immune subclass (22%) and a new immune-like subclass (15%) with high interferon signalling, cytolytic activity, expression of immune-effector cytokines and a more diverse T-cell repertoire. A 20-gene signature was able to capture ~90% of these tumours and is associated with response to immunotherapy. Proteins identified in liquid biopsies recapitulated the inflamed class with an area under the ROC curve (AUC) of 0.91; (2) The intermediate class, enriched in TP53 mutations (49% vs 29%, p=0.035), and chromosomal losses involving immune-related genes and; (3) the excluded class, enriched in CTNNB1 mutations (93% vs 27%, p<0.001) and PTK2 overexpression due to gene amplification and promoter hypomethylation. CTNNB1 mutations outside the excluded class led to weak activation of the Wnt-βcatenin pathway or occurred in HCCs dominated by high interferon signalling and type I antigen presenting genes. Conclusion: We have characterised the immunogenomic contexture of HCC and defined inflamed and non-inflamed tumours. Two distinct CTNNB1 patterns associated with a differential role in immune evasion are described. These features may help predict immune response in HCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several gene signatures capturing the inflamed components of the TME have been associated with a favourable response to ICIs69,72,78–81, but none has been clinically validated thus far.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [78]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Overall, patients with inflamed HCCs tend to have a favourable prognosis and are the most likely to have improved outcomes when receiving ICIs owing to the presence of responsive immune cells72,78.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [78]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Molecular classifications have identified classes of hepatocellular carcinoma associated with ICI responsiveness (inflamed class) and ICI resistance (excluded class).26”
From Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis (2024) · cites this paper as [26]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Inflamed tumours constitute ~30% of HCCs and exhibit extensive immune cell infiltration and immune activity, detected as increased expression of immune checkpoints (such as PD-1 or its ligand PD-L1), activation of IFN signalling and a low burden of large chromosomal alterations70,71,78.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [78]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470
Llovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., Lencioni, R., Koike, K., Zucman-Rossi, J., & Finn, R. S. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00240-3 · Cited by 7,055
Self-citationThe Immune Landscape of Cancer
Thorsson, V., Gibbs, D. L., Brown, S. D., Wolf, D., Bortone, D. S., Ou Yang, T.-H., Porta-Pardo, E., Gao, G. F., Plaisier, C. L., Eddy, J. A., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.023 · Cited by 5,870
Villanueva, A. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1713263 · Cited by 4,508
Self-citationMelanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Spranger, S., Bao, R., & Gajewski, T. F. (2015) · Nature · doi:10.1038/nature14404 · Cited by 2,830
Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma
Ally, A., Balasundaram, M., Carlsen, R., Chuah, E., Clarke, A., Dhalla, N., Holt, R. A., Jones, S. J. M., Lee, D., Ma, Y., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.046 · Cited by 2,490
D’Hulst, G., Soro-Arnaiz, I., Masschelein, E., Veys, K., Fitzgerald, G., Smeuninx, B., Kim, S., Deldicque, L., Blaauw, B., Carmeliet, P., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-13889-6 · Cited by 2,310
Immunotherapies for hepatocellular carcinoma
Llovet, J. M., Castet, F., Heikenwalder, M., Maini, M. K., Mazzaferro, V., Pinato, D. J., Pikarsky, E., Zhu, A. X., & Finn, R. S. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00573-2 · Cited by 1,843
Self-citationCheng, A.-L., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Lim, H. Y., Kudo, M., Breder, V., Merle, P., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.11.030 · Cited by 1,743
Khalifa, A. A. Z., Ichikawa, M., Dai, D., Kubo, S., Black, C. S., Peri, K., McAlear, T. S., Veyron, S., Yang, S. K., Vargas, J., et al. (2020) · eLife · doi:10.7554/elife.52760 · Cited by 1,676
The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy
Bruni, D., Angell, H. K., & Galon, J. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-020-0285-7 · Cited by 1,586
Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion
Jhunjhunwala, S., Hammer, C., & Delamarre, L. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00339-z · Cited by 1,570
Davoli, T., Uno, H., Wooten, E. C., & Elledge, S. J. (2017) · Science · doi:10.1126/science.aaf8399 · Cited by 1,347
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
Pfister, D., Núñez, N. G., Pinyol, R., Govaere, O., Pinter, M., Szydlowska, M., Gupta, R., Qiu, M., Deczkowska, A., Weiner, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03362-0 · Cited by 1,294
Self-citationHoshida, Y., Nijman, S. M. B., Kobayashi, M., Chan, J. A., Brunet, J.-P., Chiang, D. Y., Villanueva, A., Newell, P., Ikeda, K., Hashimoto, M., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1089 · Cited by 1,238
Self-citationIdentification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features
Sia, D., Jiao, Y., Martinez-Quetglas, I., Kuchuk, O., Villacorta-Martin, C., Castro de Moura, M., Putra, J., Camprecios, G., Bassaganyas, L., Akers, N., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.06.007 · Cited by 976
Self-citationRuiz de Galarreta, M., Bresnahan, E., Molina-Sánchez, P., Lindblad, K. E., Maier, B., Sia, D., Puigvehi, M., Miguela, V., Casanova-Acebes, M., Dhainaut, M., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0074 · Cited by 912
Self-citationWNT/β-catenin pathway activation correlates with immune exclusion across human cancers
Luke, J. J., Bao, R., Sweis, R. F., Spranger, S., & Gajewski, T. F. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1942 · Cited by 722
Focal Gains of VEGFA and Molecular Classification of Hepatocellular Carcinoma
Chiang, D. Y., Villanueva, A., Hoshida, Y., Peix, J., Newell, P., Minguez, B., LeBlanc, A. C., Donovan, D. J., Thung, S. N., Solé, M., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0742 · Cited by 719
Self-citationKRAS-IRF2 axis drives immune suppression and immune therapy resistance in colorectal cancer
Liao, W., Overman, M. J., Boutin, A. T., Shang, X., Zhao, D., Dey, P., Li, J., Wang, G., Lan, Z., Li, J., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.02.008 · Cited by 617
Harding, J. J., Nandakumar, S., Armenia, J., Khalil, D. N., Albano, M., Ly, M., Shia, J., Hechtman, J. F., Kundra, R., El Dika, I., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2293 · Cited by 602
Biological Consequences of MHC-II Expression by Tumor Cells in Cancer
Axelrod, M. L., Cook, R. S., Johnson, D. B., & Balko, J. M. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3200 · Cited by 516
Genomic correlates of response to immune checkpoint blockade
Keenan, T. E., Burke, K. P., & Van Allen, E. M. (2019) · Nature Medicine · doi:10.1038/s41591-019-0382-x · Cited by 448
DNA methylation‐based prognosis and epidrivers in hepatocellular carcinoma
Villanueva, A., Portela, A., Sayols, S., Battiston, C., Hoshida, Y., Méndez‐González, J., Imbeaud, S., Letouzé, É., Hernández–Gea, V., Cornellà, H., et al. (2015) · Hepatology · doi:10.1002/hep.27732 · Cited by 434
Self-citationSangro, B., Melero, I., Wadhawan, S., Finn, R. S., Abou-Alfa, G. K., Cheng, A.-L., Yau, T., Furuse, J., Park, J.-W., Boyd, Z., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.07.026 · Cited by 407
Self-citationAn osteopontin/CD44 immune checkpoint controls CD8+ T cell activation and tumor immune evasion
Klement, J. D., Paschall, A. V., Redd, P. S., Ibrahim, M. L., Lu, C., Yang, D., Celis, E., Abrams, S. I., Ozato, K., & Liu, K. (2018) · Journal of Clinical Investigation · doi:10.1172/jci123360 · Cited by 372
Intratumoral heterogeneity and clonal evolution in liver cancer
Losic, B., Craig, A. J., Villacorta-Martín, C., Martins-Filho, S. N., Akers, N. K., Chen, X., Ahsen, M. E., von Felden, J., Labgaa, I., D’Avola, D., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-14050-z · Cited by 371
Self-citationA Pan-cancer Landscape of Interactions between Solid Tumors and Infiltrating Immune Cell Populations
Tamborero, D., Rubio-Pérez, C., Muiños, F., Sabarinathan, R., Piulats, J. M., Muntasell, A., Dienstmann, R., López-Bigas, N., & González-Pérez, A. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3509 · Cited by 356
Rebouissou, S., Franconi, A., Caldéraro, J., Letouzé, É., Imbeaud, S., Pilati, C., Nault, J., Couchy, G., Laurent, A., Balabaud, C. P., et al. (2016) · Hepatology · doi:10.1002/hep.28638 · Cited by 342
Lachenmayer, A., Alsinet, C., Savic, R., Cabellos, L., Toffanin, S., Hoshida, Y., Villanueva, A., Minguez, B., Newell, P., Tsai, H.-W., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2322 · Cited by 306
Self-citation(2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00245-6 · Cited by 265
Zucman-Rossi, J., Benhamouche, S., Godard, C., Boyault, S., Grimber, G., Balabaud, C., Cunha, A. S., Bioulac-Sage, P., & Perret, C. (2007) · Oncogene · doi:10.1038/sj.onc.1209824 · Cited by 256
Cancer-Specific Loss of p53 Leads to a Modulation of Myeloid and T Cell Responses
Blagih, J., Zani, F., Chakravarty, P., Hennequart, M., Pilley, S. E., Hobor, S., Hock, A. K., Walton, J. B., Morton, J. P., Gronroos, E. C., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2019.12.028 · Cited by 175
Zhou, X., Singh, M., Sanz Santos, G., Guerlavais, V., Carvajal, L. A., Aivado, M., Zhan, Y., Oliveira, M. M. S., Westerberg, L. S., Annis, D. A., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1741 · Cited by 169
Hsu, C., Ou, D., Bai, L., Chen, C., Lin, L., Huang, S.-F. K., Cheng, A., Jeng, Y., & Hsu, C. (2021) · Liver Cancer · doi:10.1159/000515305 · Cited by 151
Molecular Markers of Response to Anti-PD1 Therapy in Advanced Hepatocellular Carcinoma
Haber, P. K., Castet, F., Torres-Martin, M., Andreu-Oller, C., Puigvehí, M., Miho, M., Radu, P., Dufour, J.-F., Verslype, C., Zimpel, C., et al. (2023) · Gastroenterology · doi:10.1053/j.gastro.2022.09.005 · Cited by 145
Self-citationvon Felden, J., Craig, A. J., García‐Lezana, T., Labgaa, I., Haber, P. K., D’Avola, D., Asgharpour, A., Dieterich, D. T., Bonaccorso, A., Torres‐Martín, M., et al. (2020) · Oncogene · doi:10.1038/s41388-020-01519-1 · Cited by 139
Self-citationHong, J. Y., Cho, H. J., Sa, J. K., Liu, X., Ha, S. Y., Lee, T., Kim, H., Kang, W., Sinn, D. H., Gwak, G., et al. (2022) · Genome Medicine · doi:10.1186/s13073-021-00995-8 · Cited by 136
Johnson, A. M., Bullock, B., Neuwelt, A. J., Poczobutt, J. M., Kaspar, R. E., Li, H. Y., Kwak, J., Hopp, K., Weiser-Evans, M. C. M., Heasley, L. E., et al. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.1900778 · Cited by 134
Abitbol, S., Dahmani, R., Coulouarn, C., Ragazzon, B., Mlecnik, B., Senni, N., Savall, M., Bossard, P., Sohier, P., Drouet, V., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.12.018 · Cited by 117
Kriegsman, B. A., Vangala, P., Chen, B. J., Meraner, P., Brass, A. L., Garber, M., & Rock, K. L. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1900475 · Cited by 114
Cadoux, M., Caruso, S., Pham, S., Gougèlet, A., Pophillat, C., Riou, R., Loesch, R., Colnot, S., Nguyễn, C. T., Caldéraro, J., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.01.017 · Cited by 75
Bassaganyas, L., Pinyol, R., Esteban-Fabró, R., Torrens, L., Torrecilla, S., Willoughby, C. E., Franch-Expósito, S., Vila-Casadesús, M., Salaverria, I., Montal, R., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1497 · Cited by 58
Self-citationFranch-Expósito, S., Bassaganyas, L., Vila-Casadesús, M., Hernández-Illán, E., Esteban-Fabró, R., Díaz-Gay, M., Lozano, J., Castells, A., Llovet, J., Castellví-Bel, S., et al. (2020) · eLife · doi:10.7554/elife.50267 · Cited by 56
Self-citationMethylation of immune synapse genes modulates tumor immunogenicity
Berglund, A., Mills, M. N., Putney, R. M., Hamaidi, I., Mulé, J. J., & Kim, S. (2019) · Journal of Clinical Investigation · doi:10.1172/jci131234 · Cited by 54
Roy, A. (2022) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2022.07.003 · Cited by 41
Molecular markers of response to anti-PD1 therapy in advanced hepatocellular carcinoma.
Haber, P. K., Torres‐Martín, M., Dufour, J., Verslype, C., Marquardt, J. U., Galle, P. R., Vogel, A., Meyer, T., Labgaa, I., Roberts, L. R., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.15_suppl.4100 · Cited by 37
Self-citationAtezolizumab plus Bevacizumab: A Novel Breakthrough in Hepatocellular Carcinoma
Castet, F., Willoughby, C. E., Haber, P. K., & Llovet, J. M. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4706 · Cited by 20
Self-citation
Research works printed but not linked: 2
- Esteban-Fabró R , Willoughby CE , Piqué‐Gili M . Data from: cabozantinib enhances anti-PD1 efficacy and elicits a neutrophil-based immune response in murine models: implications for human HCC. gene expression Omnibus. Available: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE174570
- Hsu, 2021, Exploring markers of exhausted CD8 T cells to predict response to immune checkpoint inhibitor therapy for hepatocellular carcinoma, Liver Cancer, 10, 346, 10.1159/000515305 · DOI
Cited by
Sorted by citations
AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma
Singal, A. G., Llovet, J. M., Yarchoan, M., Mehta, N., Heimbach, J. K., Dawson, L. A., Jou, J. H., Kulik, L. M., Agopian, V. G., Marrero, J. A., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000466 · Cited by 2,052
“Aside from diagnostic purposes, HCC biopsies can be informative of molecular and immune classes of HCC, [9] oncogenic mutations associated with immune excluded phenotypes, [128] and gene signatures predictive of response to immunotherapy.”
Self-citationEvolving therapeutic landscape of advanced hepatocellular carcinoma
Yang, C. G., Zhang, H., Zhang, L., Zhu, A. X., Bernards, R., Qin, W., & Wang, C. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00704-9 · Cited by 747
Molecular pathogenesis and systemic therapies for hepatocellular carcinoma
Llovet, J. M., Pinyol, R., Kelley, R. K., El-Khoueiry, A., Reeves, H. L., Wang, X. W., Gores, G. J., & Villanueva, A. (2022) · Nature Cancer · doi:10.1038/s43018-022-00357-2 · Cited by 498
Self-citationPrecision treatment in advanced hepatocellular carcinoma
Yang, X., Yang, C. G., Zhang, S., Geng, H., Zhu, A. X., Bernards, R., Qin, W., Fan, J., Wang, C., & Gao, Q. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.01.007 · Cited by 466
Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma
Llovet, J. M., Pinyol, R., Yarchoan, M., Singal, A. G., Marron, T. U., Schwartz, M., Pikarsky, E., Kudo, M., & Finn, R. S. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00868-0 · Cited by 391
Self-citation
Metadata
- Authors
- Montironi, C., Castet, F., Haber, P. K., Pinyol, R., Torres-Martin, M., Torrens, L., Mesropian, A., Wang, H., Puigvehi, M., Maeda, M., Leow, W. Q., Harrod, E., Taik, P., Chinburen, J., Taivanbaatar, E., Chinbold, E., Solé Arqués, M., Donovan, M., Thung, S., Neely, J., Mazzaferro, V., Anderson, J., Roayaie, S., Schwartz, M., Villanueva, A., Friedman, S. L., Uzilov, A., Sia, D., & Llovet, J. M.
- Affiliations
- Hospital Clínic de Barcelona (ES)
- Tisch Cancer Institute (US)
- Translational Research in Hepatic Oncology, Liver Unit, IDIBAPS, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain
- Sema4 (United States) (US)
- Mount Sinai Liver Cancer Program, Division of Liver Diseases, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA
- Singapore General Hospital (SG)
- Royal Surrey County Hospital (GB)
- Hepato-Pancreatico-Biliary Surgery Department, National Cancer Center, Ulaanbaatar, Mongolia
- Bristol-Myers Squibb (United States) (US)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- White Plains Hospital (US)
- Institució Catalana de Recerca i Estudis Avançats (ES)
- Corresponding author
- Llovet, Josep M
- ORCID
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2022-02-23
- Volume
- 72
- Issue
- 1
- Pages
- 129-140
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- PMC
- PMC9395551
- OpenAlex
- W4213062169
- Cited by
- 253
- References
- 49
- Citations by year
- 2026: 48 · 2025: 52 · 2024: 66 · 2023: 67 · 2022: 19
- FWCI
- 21.60
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- Locations
- Gut (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- Funders
- Dr. Franklin M. Klion Young Scientist Research Award (N/A)
- Generalitat de Catalunya (PERIS (SLT017/20/000206))
- National Cancer Institute (P30-CA196521)
- PhD Scientist Innovative Research Award (N/A)
- Instituto de Salud Carlos III (Rio Hortega grant (CM19/00039))
- Samuel Waxman Cancer Research Foundation (N/A)
- Acadèmia de Ciències Mèdiques i de la Salut de Catalunya i de Balears (N/A)
- Cancer Research UK (HUNTER, Ref. C9380/A26813)
- Associazione Italiana per la Ricerca sul Cancro (HUNTER, Ref. C9380/A26813)
- U.S. Department of Defense (CA150272P3)
- Tisch Cancer Institute (N/A)
- Horizon 2020 Framework Programme (HEPCAR, Ref. 667273-2)
- Deutsche Forschungsgemeinschaft (DFG: HA 8754/1-1)
- Fundación Científica Asociación Española Contra el Cáncer (CLJUN20007CAST, HUNTER, Ref. C9380/A26813)
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (SAF2016-76390)
- Agència de Gestió d’Ajuts Universitaris i de Recerca (SGR-1358)
- Bristol-Myers Squibb (N/A)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK128289, R01-128289, R01-56621)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- hepatocellular carcinoma, immune evasion, immunotherapy response prediction, interferon signaling, T cell receptor repertoire, TP53 mutation, CTNNB1 mutation, Wnt/β-catenin signaling, promoter hypomethylation, liquid biopsy, gene expression signatures, immune-related genes
- MeSH terms
- Carcinoma, Hepatocellular, Humans, Interferons, Liver Neoplasms, Mutation, DNA Methylation, Wnt Signaling Pathway
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
